«Histopathology is critical to establish a diagnosis based on microscopic tissue examination, but is also of great importance to medical research protocols such as The PIONeeR Project. At Hôpital Nord, we are in charge of processing PIONeeR patient biopsies and performing primary histopathological examination.»
Trained as a laboratory technician, I joined the pathology laboratory at Hôpital Nord 16 years ago, where I specialized in immunolabeling techniques and am today in charge of histopathology processing for The PIONeeR Project.
To summarize sample processing at our service, we typically receive either a biopsy or a surgical resection that we dehydrate before embedding in paraffin blocks. The embedded tissue is sectioned into slices of 3 to 4 µm and mounted on glass slides. A subset of these slides is used for HPS staining – a technique that uses a combination of three stains, hematoxylin, phloxine and saffron, to reveals the histology of a sample – and is analyzed by pathologists within the service to establish a diagnosis. Other slides are used for complementary analyses, including immunolabeling, immunofluorescence and various molecular biology techniques.
Histopathological analyses are critical to establish a diagnosis based on microscopic tissue examination, but are also of great importance in the context of medical research protocols, for example to identify biomarkers that would predict response to a given treatment. In the case of the PIONeeR Project, we are confronted with one challenge, which is that we need to be able to prepare at least 22 slides from each patient biopsy in order to complete the full panel of biomarker analyses dictated by the project’s protocol. Among the 22 slides, 3 are used for HPS staining to assess the histology of the sample throughout the sections, and 1 is used to reveal PD-L1 and CD8 proteins by immunolabeling. The rest of the slides are sent off to HalioDx to explore the potential of new biomarkers of response to immunotherapy in lung cancer patients.#clinique #recherche
Education is also one of the strategic components of the Marseille Immunopole project
AMU, AP-HM, VRCM
MI both accelerates research and development in immuno-oncology and offers cancer patients more options in terms of diagnostics and treatments, as well as more innovative clinical trials.
AMU, Gustave Roussy, The Pioneer Project
“Projects like PIONeeR allow us to contribute to the understanding of resistance to immunotherapy while opening clinical research to patients in Corsica, who, until recently, had no choice other than to fly to Marseille or Paris for such opportunities.”
Centre Hospitalier, Clinique Maymard, Bastia
We and our patients are resolutely committed to the Marseille Immunopôle; patients no longer wish to be simple "providers of biological samples", but full participants in the research process.